{
    "clinical_study": {
        "@rank": "85553", 
        "arm_group": [
            {
                "arm_group_label": "D-18F FPM", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "L-18F FPM", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and potential effectiveness of the\n      imaging compound 18F FPM for finding sites of malignancies."
        }, 
        "brief_title": "Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent obtained prior to any protocol-specific procedures\n\n          -  Male and female patients with histologically confirmed squamous cell carcinoma\n\n          -  At least one site of active malignancy, as demonstrated on the pre-study 18F FDG\n             PET/CT scan performed as part of routine clinical care\n\n          -  Age >/= 18 years\n\n          -  Life expectancy >/= 3 months\n\n          -  ECOG Performance score of 0-2\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding females\n\n          -  Systemic anti-neoplastic therapy within the 2 weeks prior to the pre-study 18F FDG\n             PET/CT scan until after the 18F FPM PET/CT scan\n\n          -  Any serious medical condition which the investigator feels may interfere with the\n             procedures or evaluations of the study\n\n          -  Patients unwilling or unable to comply with protocol or with a history of\n             non-compliance or inability to grant informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755650", 
            "org_study_id": "11/31"
        }, 
        "intervention": {
            "arm_group_label": [
                "D-18F FPM", 
                "L-18F FPM"
            ], 
            "intervention_name": "18F FPM", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "18F FPM", 
            "PET/CT", 
            "microdosing"
        ], 
        "lastchanged_date": "December 19, 2012", 
        "location": {
            "contact": {
                "email": "Ben.Solomon@petermac.org", 
                "last_name": "Ben Solomon", 
                "phone": "61 3 9656 1111"
            }, 
            "facility": {
                "address": {
                    "city": "East Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria"
                }, 
                "name": "Peter MacCallum Cancer Centre"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 0 Exploratory Microdosing Study of S-(3-18Ffluoropropyl)Homocysteine Hydrochloride; 18FFPM Using PET/CT in Patients With a Variety of Malignancies.", 
        "overall_contact": {
            "email": "sonia.mailer@crcbid.com.au", 
            "last_name": "Sonia Mailer", 
            "phone": "61 3 9467 6277"
        }, 
        "overall_official": {
            "affiliation": "Peter MacCallum Cancer Centre, Australia", 
            "last_name": "Ben Solomon", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety of D-18F FPM and L-18F FPM administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F FPM administration", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 28 days following 18F FPM administration (+/- 7 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755650"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of injected D-18F FPM and L-18F FPM dose in organs of interest.", 
                "safety_issue": "No", 
                "time_frame": "10, 30, 60 and 120 minutes post 18F FPM administration"
            }, 
            {
                "measure": "Percentage of unmetabolized D-18F FPM and L-18F FPM in plasma and urine after radiotracer administration.", 
                "safety_issue": "No", 
                "time_frame": "30 (plasma only) and 90 (plasma and urine) minutes post 18F FPM administration"
            }, 
            {
                "measure": "Absorbed organ doses expressed as micro Sv/MBq of administered D-18F FPM and L-18F FPM, and whole body dose expressed as milliSv/200MBq of administered dose", 
                "safety_issue": "No", 
                "time_frame": "10, 30, 60 and 120 minutes post 18F FPM administration"
            }
        ], 
        "source": "Cooperative Research Centre for Biomedical Imaging Development", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cooperative Research Centre for Biomedical Imaging Development", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}